Merck & Co 1st-qtr earnings just beat expectations; wins Mylan patent dispute
US drug giant Merck & Co sales that global sales in the first-quarter of 2012 increased 1% to $11.7 billion, shy of analysts’ consensus expectations of $11.82 billion, driven by growth of 3% in pharmaceuticals (6% excluding the Impact of the J&J arbitration settlement), 8% in animal health and 7% in consumer care.
Non-GAAP earnings per share, excluding certain items, were $0.99 a share, up 7.6% on the like year-earlier quarter and beating expectations by a penny. GAPP net income was $1.74 billion, a leap of 66.6%, with non-GAPP net income up 6.4% at $3.04 billion. The company said 2012 revenue should be about the same as last year - $48 billion - with profit at $3.75 to $3.85 a share. Both are within analysts' targets.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze